Hypopigmentation Disorder Treatment Market Trends, Size 2031

[Research Report] Hypopigmentation disorder treatment market value is expected to grow from US$ 4.4 billion in 2023 to US$ 6.7 billion by 2031; the market is estimated to record a CAGR of 5.41% from 2023 to 2031.

Market Insights and Analyst View:

Hypopigmentation disorders may further develop into depigmentation disorders. It is a condition wherein skin pigment levels are below optimum, unlike depigmentation conditions that occur due to the complete removal of pigments. Major factors driving the hypopigmentation disorder treatment market growth are the rising awareness related to hypopigmentation disorders, technological advancements in aesthetic treatments, and a continuous surge in the aging population. Moreover, increasing incidences of disorders related to hypopigmentation, such as albinism, post-hypopigmentation, and vitiligo, are anticipated to fuel the hypopigmentation disorders treatment market in the coming years. Further, growing consumer spending on skin health and awareness related to treatment is predicted to benefit this market in the near future. The introduction of natural and plant-based components is expected to bring hypopigmentation disorder treatment market trends in the coming years, as these products have been critical in meeting the global demand for cosmeceutical products so far. The cost of cosmetic treatments and surgery, on the other hand, restricts the market growth.

According to the National Clinical Trials (NCT) registry, in June 2020, Incyte Corporation conducted a phase II clinical trial for Ruxolitinib to evaluate its safety and efficacy in treating vitiligo in subjects enrolled in the US. Thus, the increasing number of clinical trials associated with hypopigmentation disorders is another key factor bolstering the market.

Growth Drivers and Challenges:

Increasing Prevalence of Hypopigmentary Disorders Propels Market Growth

Pityriasis alba, vitiligo, albinism, and post-inflammatory hypopigmentation are among the major disease indications associated with hypopigmentation disorders. Vitiligo is a commonly occurring disease indication across the world. According to a study published in the Dermatology Practical and Conceptual in December 2023, Vitiligo is a prevalent skin condition affecting both genders. Nonetheless, it is more prevalent in females, and more than 60% of patients experience disease onset before the age of 30. Rising incidences and prevalence of vitiligo are anticipated to further contribute to the growing demand for hypopigmentation treatments.

According to an article published in Zagazig University Medical Journal in March 2023, hypopigmentation disorders are a common group of dermatoses in pediatrics; the prevalence of hypopigmentation disorders varies from country to country, ranging from 3.6% to 9.9%. Furthermore, the advent and adoption of minimally invasive procedures, shorter hospital admittance time, and lesser pain and fewer complications associated with procedures have been pivotal for the growing popularity of minimally invasive procedures. According to the American Society of Plastic Surgeons (ASPS) in 2021, the number of minimally invasive cosmetic procedures performed in the US has surged by nearly 200% since 2000. Thus, the growing preference for minimally invasive cosmetic procedures further propels the hypopigmentation disorder treatment market growth. On the other hand, the cost of light therapy for disease indications such as vitiligo and albinism is high. Moreover, surgical procedures to treat vitiligo procedures are highly expensive. Thus, the high cost of treatments limits their adoption, thereby limiting the growth of the hypopigmentation disorder treatment market.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Hypopigmentation Disorder Treatment Market: Strategic Insights

Market Size Value in	US$ 4.4 billion in 2023
Market Size Value by	US$ 6.7 billion by 2031
Growth rate	CAGR of 5.41% from 2023 to 2031
Forecast Period	2023-2031
Base Year	2023

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The hypopigmentation disorder treatment market analysis has been carried out by considering the following segments: treatment, disease indication, and end user. The geographic scope of the hypopigmentation disorder treatment market report includes North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:

Treatment-Based Insights

Based on treatment, the market is segmented into topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others. The topical drugs segment held the largest hypopigmentation disorder treatment market share in 2023 and is anticipated to register the highest CAGR during 2023–2031.

Disease Indication-Based Insights

Based on disease indication, the hypopigmentation disorder treatment market is segmented into pityriasis alba, albinism, vitiligo, post-inflammatory hypopigmentation, and others. The vitiligo segment held a significant market share by 2023, and it is expected to register the highest CAGR during 2023–2031.

End User-Based Insights

In terms of end user, the market is categorized into aesthetics clinics, dermatology centers, and hospitals. The aesthetics clinics segment held the largest hypopigmentation disorder treatment market share in 2023; it is further anticipated to register the highest CAGR in the market during 2023–2031.

Access Data

Regional Analysis:

North America held the largest share of the hypopigmentation disorder treatment market in 2023, and it is projected to maintain its dominance (in terms of share) during the forecast period. The US dominates the market in this region (with the largest share) and the world. Well-established healthcare infrastructure, rising consciousness among people about their skin health, increasing prevalence of diseases associated with hypopigmentation disorders, and significant presence of companies that provide attractive treatment options for patients with post-inflammatory hyperpigmentation are among the noteworthy factors driving the market growth in North America. Further, beauty concerns with the rising beauty standards among Asians, a large number of companies entering the market, and the continued growth of established players are among the key factors contributing to the expansion of the hypopigmentation disorder treatment market size in Asia Pacific.

Competitive Landscape and Key Companies:

The hypopigmentation disorder treatment market forecast can help stakeholders in this marketplace plan their growth strategies. Allergan, SkinCeuticals, Pierre Fabre Group, Incyte Corporation, Episciences Inc., Phio Pharmaceuticals, Obagi Cosmeceuticals LLC, Alvogen, Bella Aurora, AbbVie are a few key companies profiled in the hypopigmentation disorder treatment market report. These companies focus on expanding their product offerings to meet the growing consumer demand across the world. Their global presence allows them to serve many customers.